Millennium Capital Advisors’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-2,083
Closed -$222K 126
2024
Q1
$222K Sell
2,083
-307
-13% -$30.9K 0.16% 110
2023
Q4
$238K Sell
2,390
-160
-6% -$13.5K 0.18% 106
2023
Q3
$263K Sell
2,550
-15
-0.6% -$1.67K 0.22% 81
2023
Q2
$312K Buy
2,565
+210
+9% +$28K 0.26% 70
2023
Q1
$362K Buy
2,355
+557
+31% +$91.9K 0.32% 57
2022
Q4
$323K Buy
+1,798
New +$294K 0.33% 62

Other funds holding MRNA

Millennium Capital Advisors's MRNA Position: Q2 2024 in Review

Millennium Capital Advisors sold out of Moderna (MRNA) in Q2 2024, closing a stake of 2,083 shares — an estimated $222K sold.

Millennium Capital Advisors first reported a position in MRNA in Q4 2022 and held it in 6 quarters. The position peaked at $362K in Q1 2023. 954 funds tracked by Wall St. Rank hold MRNA as of Q2 2024.

  • Millennium Capital Advisors reported no remaining Moderna position as of Q2 2024 after selling out during the quarter.
  • Millennium Capital Advisors sold 2,083 Moderna shares in Q2 2024, an estimated $222K.
  • Millennium Capital Advisors first reported a position in Moderna in Q4 2022 and held it in 6 quarters.
  • Millennium Capital Advisors's Moderna position peaked at $362K in Q1 2023.
  • 954 funds tracked by Wall St. Rank held Moderna as of Q2 2024.

Based on Millennium Capital Advisors's 13F filing for Q2 2024, filed 18 Feb 2026.